Primary effusion and plasmablastic lymphoma
CHOP or EPOCH-based chemotherapy with antiretroviral therapy; bortezomib-containing regimens for plasmablastic; clinical trials (pomalidomide, daratumumab, anti-IL-6).
Bortezomib was the first proteasome inhibitor: it jams the cell's protein-recycling machine, which antibody-factory plasma cells cannot tolerate.
The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.
The third-generation thalidomide analogue for myeloma that has failed lenalidomide, and since 2020 also approved in the US for Kaposi sarcoma.
Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Thrombocytopenia · Subcutaneous arm of MMY-3021, N=147 | 30% | 8% |
| Peripheral neuropathy · Subcutaneous arm of MMY-3021 (subcutaneous versus intravenous, relapsed myeloma), N=147; 50% any grade and 15% grade 3 or higher intravenously | 37% | 6% |
- Start at 0.7 mg/m² in moderate or severe impairment.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (with Rd) · MAIA daratumumab-lenalidomide-dexamethasone arm; 35.3% with lenalidomide-dexamethasone | - | 50% |
| Pneumonia · MAIA daratumumab-lenalidomide-dexamethasone arm (13.7%); 7.9% with lenalidomide-dexamethasone | - | 14% |
| Infusion/injection reaction · Subcutaneous arm of COLUMBA, N=260; 34% any grade with intravenous daratumumab | 13% | 2% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Smoking induces CYP1A2 and lowers exposure by about a third.
- Reduce to 75% for CrCl 15-50.
- Between Bortezomib, Daratumumab, Pomalidomide and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- Which side effects of Bortezomib or Daratumumab are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (primary effusion and plasmablastic lymphoma), which of the standard options do you recommend and why?Why: Guideline options include: CHOP or EPOCH-based chemotherapy with antiretroviral therapy; bortezomib-containing regimens for plasmablastic; clinical trials (pomalidomide, daratumumab, anti-IL-6).
- Am I a candidate for Bortezomib, Daratumumab, Pomalidomide or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.